• Sonuç bulunamadı

Combined therapy with probiotic VSL#3 and omega-3 fatty acids attenuates colonic injury and inflammation in chronic DNBS-induced colitis in mice (vol 69, pg 135, 2021)

N/A
N/A
Protected

Academic year: 2024

Share "Combined therapy with probiotic VSL#3 and omega-3 fatty acids attenuates colonic injury and inflammation in chronic DNBS-induced colitis in mice (vol 69, pg 135, 2021)"

Copied!
1
0
0

Yükleniyor.... (view fulltext now)

Tam metin

(1)

e-ISSN 1734-9168 Folia Biologica (Kraków), vol. 70 (2022), No 1 http://www.isez.pan.krakow.pl/en/folia-biologica.html https://doi.org/10.3409/fb_70-1.05

Corrigendum to: Combined Therapy with Probiotic VSL#3 and Omega-3 Fatty Acids Attenuates Colonic Injury and Inflammation in Chronic DNBS-induced

Colitis in Mice

Accepted February 14, 2022 Published online February 16, 2022 Issue online April 28, 2022

Corrigendum ILKTACH.Y., KIZILTANG., LANPIRA.D., OZANSOYM., GUNALM.Y., TOGAYS.O., KESKINI., OZDEMIR E.M., KILICU. 2022. Corrigendum to: Combined therapy with probiotic VSL#3 and omega-3 fatty acids attenuates colonic injury and inflammation in chronic DNBS-induced colitis in mice. Folia Biologica (Kraków)70: 43.

https://doi.org/10.3409/fb_70-1.05

____________________________________________________________________________________________________________

Original article: ILKTACH.Y., KIZILTANG., LANPIRA.D., OZANSOYM., GUNALM.Y., TOGAYS.O., KESKINI., OZDEMIRE.M., KILICU. 2021. Combined therapy with probiotic VSL#3 and omega-3 fatty acids attenuates colonic injury and inflammation in chronic DNBS-induced colitis in mice. Folia Biologica (Kraków)69: 135-146.

https://doi.org/10.3409/fb_69-3.15

We published the abovementioned article about probiotic mixture VSL#3 on October 6, 2021. Since the product was named VSL#3 in our purchasing process in early 2016, it is referred to as VSL#3 in our article. In addition, the product currently known as VSL#3 is not the same as De Simone Formulation.

De Simone Formulation is now available as Visbiome® in the United States and Vivomixx® in Europe. The authors would like to apologise for any inconvenience caused

Key words: Cytokines, probiotics, omega-3 fatty acids, inflammatory bowel diseases, colitis Havvanur Yoldas ILKTAC*, Asli Devrim LANPIR, Department of Nutrition and Dietetics, Faculty of Health Sciences, Istanbul Medeniyet University, Istanbul.

E-mail: havvanur.yoldas@medeniyet.edu.tr

Gul KIZILTAN, Department of Nutrition and Dietetics, Faculty of Health Sciences, Baskent University, Ankara.

E-mail: gkizilta@baskent.edu.tr

Mehmet OZANSOY, Department of Physiology, Faculty of Medicine, Bahcesehir University, Istanbul.

E-mail: mehmet.ozansoy@med.bau.edu.tr

Mehmet Yalcin GUNAL, Department of Physiology, Faculty of Medicine, Alanya Alaaddin Keykubat University, Antalya.

E-mail: yalcin.gunal@alanya.edu.tr

Sine Ozmen TOGAY, Department of Food Engineering, Faculty of Agriculture, Uludag University, Bursa.

E-mail: sineozmen@gmail.com

Ilknur KESKIN, Department of Histology and Embryology, Faculty of Medicine, Istanbul Medipol University, Istanbul.

E-mail: ilknurkeskin@medipol.edu.tr

Ekrem Musa OZDEMIR, Medical Research Center, Istanbul Medipol University, Istanbul.

E-mail: emozdemir@medipol.edu.tr

Ulkan KILIC, Department of Medical Biology, Faculty of Medicine, University of Health Sciences, Istanbul.

E-mail: uckilic@yahoo.com.tr ÓInstitute of Systematics and Evolution of Animals, PAS, Kraków, 2022

Open Access article distributed under the terms of the Creative Commons Attribution License (CC-BY)

http://creativecommons.org/licences/by/4.0 OPENÐACCESS

Havvanur Yoldas I LKTAC , Gul K IZILTAN , Asli Devrim L ANPIR , Mehmet O ZANSOY ,

Mehmet Y. G UNAL , Sine Ozmen T OGAY , Ilknur K ESKIN , Ekrem M. O ZDEMIR , and Ulkan K ILIC

Referanslar

Benzer Belgeler